Fish Analysis, Chromosome 16 Inversion or Translocation

Cytogenetics Test Requisition     Specimen Information       Billing Information       Contact Us      CPT Codes     Print Page

FISH ANALYSIS, CHROMOSOME 16 INVERSION or TRANSLOCATION

Pseudonyms: inv(16), t(16;16), CBFB Rearrangement, Acute Myeloid Leukemia, AML

TURNAROUND TIME: 7 to 10 days
 
 
 
TESTING METHODOLOGY: Fluorescence in situ hybridization
 
SPECIMEN REQUIREMENTS:
  • Collect: 2 mL bone marrow aspirate in sodium heparin (green); 5 mL peripheral blood in sodium heparin (green) also acceptable.
  • Minimum Collection: 1 mL bone marrow or 2 mL peripheral blood
  • Transport: bone marrow or peripheral blood in sodium heparin (green) at 20-25°C; specimen should arrive in the laboratory within 24 hours of collection
  • Stability: Ambient: 24 hours; Refrigerated: 24 hours; Frozen: unacceptable
  • Unacceptable Conditions: Frozen or clotted specimens; paraffin-embedded specimens; specimens in anticoagulants other than sodium heparin.
A Cytogenetics Laboratory Test Requisition must accompany the specimen. Contact the Cytogenetics Laboratory at 918-502-1722 to obtain further information.
 
INTERPRETIVE DATA:
 
Test Summary: Test can detect the inversion of chromosome 16 or the 16;16 translocation characteristic of AML with marked eosinophilia but also observed in AML without eosinophilia and in t-AML; it is recommended that test be performed with chromosome analysis.
 
 
Methods: A dual-color FISH analysis performed on interphase cells using a break-apart probe for the CBFB gene on chromosome 16q22 which can detect the inv(16)(p13q22) and t(16;16); analysis of 200 interphase cells; analysis of 500 interphase cells for minimal residual disease assessment.
 
Interpretation: A positive result (inversion 16 or 16;16 translocation) is reported when the percent of cells with an abnormality exceeds the normal reference range for the probes. The detection of an abnormal clone indicates a diagnosis AML with a rearrangement involving the CBFB gene. A negative result indicates no CBFB rearrangement was observed but does not rule out the presence of a neoplastic disorder.
 
FDA Approval: This test is not approved by the FDA and it should be used as an adjunct to other clinical and pathological information.
 
Indications for Use:
  • Patients with AML; establishing the percentage of neoplastic cells at diagnosis.
  • Identifying patients with AML with an inversion of chromosome 16 or a 16;16 translocation involving the CBFB gene.
  • Monitoring the CBFB rearrangement during treatment.
ADDITIONAL RESOURCES: